Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Thiol/disulphide balance as an oxidative stress marker in pseudoexfoliation glaucoma

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Glaucoma and Imaging

Venue: Poster Village: Pod 3

First Author: : T.Takmaz TURKEY

Co Author(s): :    N. Yuksel   D. Yaman   M. Arikan Yorgun   A. Senat Aydin   O. Erel  

Abstract Details

Purpose:

To evaluate plasma levels of native thiol- disulphide balance in patients with pseudoexfoliation glaucoma (PEXG) in comparison with those of age- and sex- matched healthy subjects.

Setting:

Atatürk Training and Research Hospital, Ankara, Turkey

Methods:

This prospective study included 40 patients with PEXG patients and 32 control subjects who were in routine eye examination. Plasma native thiol and disulphide levels were measured with spectrophotometric method.

Results:

The mean age of the PEXG group was 69.10±9.42 years, and the control group was 69.97±7.24 years. There was no difference between the groups in terms of age (p=0.669) and sex (p=0.089). The mean plasma native thiol level of the PEXG group (437.725±46.20 Umol/L) did not differ statistically from that of the control group (432.11±40.10 Umol/L) (p=0.589). The mean plasma disulphide level of PEXG group (21.41±7.60 Umol/L) was significantly higher than control group (17.37±8.14 Umol/L)(p=0.033). There was no significant difference between two groups in plasma native thiol/disulphide levels (p=0.116).

Conclusions:

Thiols containing a sulphydryl group are non-enzymatic antioxidants and cause disulphide structure as oxidize. Thiol-disulphide balance plays important role in oxidative stress, apoptosis, cellular events. In PEXG, systemic oxidative stress has been held responsible for pathogenesis. Increased plasma disulphide levels may show the possible role of oxidative stress in PEXG.

Financial Disclosure:

NONE

Back to previous